Rent the Runway Inc vs BIO-TECHNE Corp — how do they compare? Rent the Runway Inc trades at $1.84 (market cap $61.75M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 184× Rent the Runway Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and BIO-TECHNE Corp for 63 Days on average.
| RENT | TECH | |
|---|---|---|
Market Cap | $61.75M | $11.36B |
Volume | 193,323 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $72.61 |
52-Week Low | $1.55 | $43.31 |
Typical Hold Time | 56 Days | 63 Days |
Enterprise Value | $228.75M | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
RENT trades at $1.68, up 1.82% today, amid a bearish technical signal and mixed fundamentals. The company reported Q2 2026 revenue growth of 20.8% YoY to $97.7M, with improved gross margins, but faces negative shareholder equity of -$182.5M and a high debt-to-asset ratio of 139.62. Recent CEO appointment and multiple law firm investigations create contrasting sentiment.
Outlook remains cautious due to persistent net losses, high leverage, and legal scrutiny, though revenue growth and margin expansion offer potential upside. Risks include execution challenges and debt burden, while analyst consensus leans Hold (57.89%) with no Sell ratings.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →